1. GPCR/G Protein
  2. Vasopressin Receptor

Terlipressin 

Cat. No.: HY-12554 Purity: 99.07%
Data Sheet SDS Handling Instructions

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells.

For research use only. We do not sell to patients.
Terlipressin Chemical Structure

Terlipressin Chemical Structure

CAS No. : 14636-12-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $95 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $170 In-stock
100 mg $280 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products

Featured Recommendations

Related Screening Libraries:

Related Small Molecules:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells. Terlipressin can result in splanchnic vasoconstriction augmenting systemic arterial blood pressure with beneficial circulatory and renal effects that would be expected to also ameliorate the key pathophysiological changes responsible for the development of refractory ascites

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03107091 BioVie Inc. Cirrhosis|Ascites Hepatic July 15, 2017 Phase 2
NCT02588716 Assiut University Hepatectomy, Surgical Blood Loss, Terlipressin September 2015 Phase 2
NCT02718599 Assiut University Hemodynamics, Liver, Terlipressin December 2015 Phase 2
NCT03130127 General Hospital of Shenyang Military Region Liver Cirrhosis|Portal Hypertension|Variceal Hemorrhage|Bleeding|Esophageal and Gastric Varices June 1, 2017
NCT02059460 National Liver Institute, Egypt|Dr. Mohamed Helmi Ibrahim Afifi|Dr. Khaled Ahmed Yassen|Dr. Khalid Mousa Abouelenain|Dr. Mohamed Abdelrauf kandil|Dr. Ayman Alsebaey Qotb Alghoraieb. Acute Kidney Injury|Liver Transplantation|Terlipressin|NGAL May 2013 Phase 4
NCT00793559 Assaf-Harofeh Medical Center Septic Shock November 2008 Phase 2
NCT00089570 Orphan Therapeutics Hepatorenal Syndrome June 2004 Phase 3
NCT02970175 University Hospital, Rouen Bronchial Endoscopy January 2017 Phase 3
NCT02695862 Institute of Liver and Biliary Sciences, India Acute Variceal Bleeding February 2016
NCT01143246 Mallinckrodt HRS September 2010 Phase 3
NCT01637454 Postgraduate Institute of Medical Education and Research Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS January 2009 Phase 3
NCT00628160 Hospital Clinic of Barcelona Liver Cirrhosis|Septic Shock October 2006 Phase 2|Phase 3
NCT00369694 Aga Khan University|Ferozsons Laboratories Ltd. Hemorrhage|Esophageal Varices|Portal Hypertension August 2006 Phase 4
NCT02119884 Shanghai Zhongshan Hospital|Shandong Provincial Hospital Gastric and Esophageal Varices February 2014 Phase 4
NCT00986817 Assistance Publique - Hôpitaux de Paris Cirrhosis November 2009 Phase 3
NCT01921985 University Hospital Inselspital, Berne Liver Resection|Liver Failure November 2013 Phase 2
NCT01530711 Pere Gines|Hospital Clinic of Barcelona Cirrhosis|Hepatorenal Syndrome Type I April 2012 Phase 4
NCT02368249 University of Zurich Kidney Failure January 2020 Phase 2
NCT02770716 Mallinckrodt|Watermark Hepatorenal Syndrome May 2016 Phase 3
NCT01932151 Hospital Clinic of Barcelona Hepatorenal Syndrome December 2012
NCT01836224 Institute of Liver and Biliary Sciences, India Cirrhosis With Septic Shock October 2012
NCT01697410 First Affiliated Hospital, Sun Yat-Sen University|Guangdong Province, Department of Science and Technology|Second Affiliated Hospital, Sun Yat-Sen University|Sixth Affiliated Hospital, Sun Yat-sen University|Chinese PLA General Hospital|Beijing 302 Hospital|Shanghai Changzheng Hospital|Wuhan Union Hospital, China|Xiangya Hospital of Central South University|Anhui Provincial Hospital|First Affiliated Hospital Bengbu Medical College|Guangxi Medical University|Jinling Hospital, China|West China Hospital|Hainan People's Hospital|Health Science Center of Xi’an Jiaotong University|China Medical University, China|First People's Hospital of Foshan|ZhuHai Hospital Septic Shock January 2013
NCT02306239 Liu ZiMeng|First Affiliated Hospital, Sun Yat-Sen University Terlipressin|Septic Shock December 2014
NCT01271114 Hospital General de Ciudad Real|University of Castilla-La Mancha Septic Shock|Sepsis-associated Hypotension June 2012 Phase 3
NCT00742690 University of Padova Cirrhosis|Type 1 Hepatorenal Syndrome May 2005 Phase 2|Phase 3
NCT01335516 Ferring Pharmaceuticals Gastrointestinal Bleeding|Oesophageal Varices November 2010
NCT02489864 Sun Yat-sen University Hepatorenal Syndrome July 2015 Phase 4
NCT00287664 Hospital Clinic of Barcelona|Grant from Education Ministery from 2001-2004. Cirrhosis|Hepatorenal Syndrome February 2002 Phase 4
NCT03038503 Ramathibodi Hospital Septic Shock|Refractory Shock December 2016 Phase 3
NCT02573727 Institute of Liver and Biliary Sciences, India Acute on Chronic Liver Failure October 2015
NCT00534677 Aga Khan University Portal Hypertension|Cirrhosis|Hematemesis|Melena May 2004 Phase 4
NCT00370253 University of Turin, Italy Hepatorenal Syndrome September 2006 Phase 3
NCT00742339 University of Padova Cirrhosis|Hepatorenal Syndrome May 2005 Phase 2|Phase 3
NCT00481572 University of Roma La Sapienza Septic Shock January 2007 Phase 2
NCT03144713 Institute of Liver and Biliary Sciences, India Cirrhosis June 28, 2017
NCT00966355 Korea University Variceal Bleeding, Cirrhosis September 2006 Phase 4
NCT02311608 Shanghai Zhongshan Hospital Liver Cirrhosis|Esophageal and Gastric Varices|Hemorrhage February 2014
NCT01649037 Institute of Liver and Biliary Sciences, India Hepatorenal Syndrome August 2012
NCT02757703 Kaohsiung Veterans General Hospital. Vasoconstrictor Choice on Acute Variceal Bleeding May 2010 Phase 4
NCT01373606 Ferring Pharmaceuticals Hepatorenal Syndrome Type 1 November 2007 Phase 1|Phase 2
NCT00995839 University of Roma La Sapienza Septic Shock|Sepsis November 2008 Phase 2|Phase 3
NCT00115947 Hvidovre University Hospital Cirrhosis|Ascites December 2004 Phase 2|Phase 3
NCT01112852 National Science Council, Taiwan Esophageal Varices|Bleeding December 2006 Phase 4
NCT00863837 National Science Council, Taiwan Esophageal Variceal Rebleeding December 2006 Phase 4
NCT02468063 Institute of Liver and Biliary Sciences, India Cirrhosis With Septic Shock May 2015
NCT01640964 Novartis Pharmaceuticals|Novartis Compensated Cirrhosis and Portal Hypertension April 2013 Phase 2
NCT02788240 Institute of Liver and Biliary Sciences, India Acute on Chronic Liver Failure May 2016
NCT02726620 Vanderbilt University Medical Center|UMC Utrecht Hypotension January 2017
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 0.8148 mL 4.0738 mL 8.1475 mL
5 mM 0.1630 mL 0.8148 mL 1.6295 mL
10 mM 0.0815 mL 0.4074 mL 0.8148 mL
References
M.Wt

1227.37

Formula

C₅₂H₇₄N₁₆O₁₅S₂

CAS No.

14636-12-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 12.3 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Terlipressin
Cat. No.:
HY-12554
Quantity: